Home    Back

Rubidium    (DrugBank: Rubidium)

2 diseases
IDDisease name (Link within this page)Number of trials
84Sarcoidosis2
86Pulmonary arterial hypertension1

84. Sarcoidosis    [ 143 clinical trials,   221 drugs,   (DrugBank: 79 drugs),   82 drug target genes,   165 drug target pathways]
Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 143 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03048097
(ClinicalTrials.gov)		February 1, 20172/2/2017Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 Myocardial Perfusion Imaging for Evaluation of Cardiac SarcoidosisSarcoidosisDrug: Fluorodeoxyglucose;Drug: Rubidium;Diagnostic Test: FDG-PET/CT with Rb82 Myocardial Perfusion ImagingYale UniversityNULLCompleted18 YearsN/AAll15Early Phase 1United States
2NCT01648933
(ClinicalTrials.gov)		July 201212/4/2012Perfusion Analysis Using Rubidium in Cardiac SarcoidosisPerfusion Analysis Using Rubidium in Cardiac SarcoidosisSarcoidosisRadiation: Rubidium PETAssistance Publique - Hôpitaux de ParisNULLCompleted18 YearsN/AAll53N/AFrance

86. Pulmonary arterial hypertension    [ 1,083 clinical trials,   667 drugs,   (DrugBank: 122 drugs),   98 drug target genes,   185 drug target pathways]
Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 1,083 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03344159
(ClinicalTrials.gov)		April 1, 201828/9/2017Spironolactone Therapy in Chronic Stable Right HF TrialSpironolactone Therapy in Chronic Stable Right HF TrialChronic Right-Sided Heart Failure;Pulmonary Arterial Hypertension;Pulmonary Hypertension, Primary, 2;Pulmonary Hypertension, Primary, 3;Pulmonary Hypertension, Primary, 4;Cardiomyopathy Right VentricularDrug: Spironolactone;Drug: Placebo;Radiation: PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82;Diagnostic Test: Cardiac MRI (Gadolinium enhanced)Ottawa Heart Institute Research CorporationNULLSuspended18 YearsN/AAll30Phase 4Canada